long intergenic non-protein coding RNA 635Genealiases: []
Q-omics provides the consensus-scored LINC00635 profile across patient tissues and cancer cell-line models. LINC00635 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC00635 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, LINC00635 RNA expression shows 7,880 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight KIRP, BRCA, and KICH as cancer lineages where LINC00635 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00635 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00635 survival associations across molecular data types. LINC00635 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00635 RNA expression–survival associations across cancer types. High LINC00635 expression shows unfavorable associations in COAD, CESC and ACC, but favorable associations in KIRP, BLCA and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC00635 RNA expression.
This table summarizes LINC00635 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00635. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00635 shows lower tumor expression in BRCA and higher tumor expression in LUSC, KIRP, THCA and HNSC. The BRCA box plot shows higher LINC00635 RNA expression in normal versus tumor tissue (log2 FC = −0.013, t-test p = .002).
This table shows molecular features associated with LINC00635 in patient tissues and cancer cell lines. In patient samples, LINC00635 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set.
